2,554 results match your criteria Cardiorenal medicine[Journal]
J Cardiol Cases 2013 Mar 11;7(3):e82-e85. Epub 2013 Jan 11.
Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan.
Atherosclerotic renal artery stenosis (ARAS) can cause resistant hypertension, progressive renal failure and/or cardiorenal syndrome. Although no randomized study to demonstrate the superiority of renal stenting over medical treatment is available, a case-sensitive approach is required for the treatment of ARAS. Here, we describe a case report of a symptomatic ARAS patient with a solitary functioning kidney in which successful detection of ARAS by ultrasonography examination with the Doppler method and timely renal artery stenting were performed. Read More
J Cardiol Cases 2012 Feb 21;5(1):e39-e43. Epub 2011 Nov 21.
Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan.
Background: We report a rare case of acute pulmonary embolism (PE) induced by urinary retention and bladder distention with benign prostatic hyperplasia (BPH).
Case Report: A 76-year-old male with BPH presented to the hospital with anuria of 24 h duration and abdominal distention. Physical examination revealed tenderness and distention of the lower abdomen and a swollen right leg. Read More
Cardiorenal Med 2018 Dec 11;9(2):69-82. Epub 2018 Dec 11.
Harold Simmons Center of Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California Irvine School of Medicine, Orange, California,
Background: Residual kidney function (RKF) is often expected to inevitably and rapidly decline among hemodialysis patients and, hence, has been inadvertently ignored in clinical practice. The importance of RKF has been revisited in some recent studies. Given that patients with end-stage renal disease now tend to initiate maintenance hemodialysis therapy with higher RKF levels, there seem to be important opportunities for incremental hemo-dialysis by individualizing the dose and frequency according to their RKF levels. Read More
Kidney Blood Press Res 2018 Dec 7;43(6):1832-1841. Epub 2018 Dec 7.
Background/aims: Cardiorenal syndrome type 1(CRS1) is a serious clinical condition in patients with acute heart failure (AHF) associated with adverse clinical outcomes. Although several biomarkers for identifying CRS1 have been reported, early and accurate predicting CRS1 still remains a challenge. This study was aimed to develop and validate an individualized predictive nomogram for the risk of CRS1 in patients with AHF. Read More
Heart Vessels 2018 Dec 7. Epub 2018 Dec 7.
Division of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.
Anatomical measurements obtained by intracoronary imaging devices are reported to correlate significantly with fractional flow reserve (FFR). Instantaneous wave-free ratio (iFR) is a nonhyperemic index of stenosis severity with discordant reports regarding its accuracy in relation to FFR. There is no information on the correlation of iFR with measurements derived from intracoronary imaging devices. Read More
Sci Rep 2018 Dec 10;8(1):17757. Epub 2018 Dec 10.
BIOMED - Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium.
Venous congestion is an important contributor to worsening renal function in heart failure and the cardiorenal syndrome. In patients, it is difficult to study the effects of isolated venous congestion on organ function. In this study, the consequences of isolated abdominal venous congestion on morphology and function of the kidneys, liver and heart were studied in a rat model. Read More
Can J Cardiol 2018 Dec 20;34(12):1687.e13-1687.e15. Epub 2018 Aug 20.
Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan.
A 28-year-old man without coronary risk factors was admitted to the hospital with acute coronary syndromes (ACS). The angiogram and intravascular ultrasound revealed myocardial bridge (MB) in the mid-left anterior descending artery and flow-limiting plaque located 15.4 mm proximal to MB. Read More
Peptides 2018 Nov 30;112:43-47. Epub 2018 Nov 30.
Department of Clinical Biochemistry, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Cardiorenal physiology (Mayo Clinic, Rochester, MN, USA; Copenhagen University, Denmark.
Drugs facilitating the cardioprotective effects of natriuretic peptides are introduced in heart failure treatment. ANP and BNP also stimulate lipolysis and increase circulating concentrations of free fatty acids (FFAs); an aspect, however, thought to be confined to primates. We examined the lipolytic effect of natriuretic peptide infusion in healthy young men and evaluated the effect in a porcine model of myocardial ischemia and reperfusion. Read More
Rev Soc Bras Med Trop 2018 Nov-Dec;51(6):869-872
Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, AM, Brasil.
Cardiorenal syndrome type 1 (CRS 1) occurs when acute heart failure leads to acute kidney injury. There are several etiologies of CRS 1, including Chagas disease. Here, we present the first case report of CRS 1 in a patient with acute Chagas disease. Read More
Biomed Res Int 2018 1;2018:2817045. Epub 2018 Nov 1.
Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Abnormal angiogenesis plays a major role in the development of early stage diabetic nephropathy. Vascular endothelial growth factor (VEGF) is a classical proangiogenic factor that regulates abnormal glomerular angiogenesis linked to glomerular hypertrophy in the early stage of diabetic nephropathy. Leucine-rich -2-glycoprotein-1 (LRG1) was recently reported as a novel proangiogenic factor that is expressed in endothelial cells and promotes angiogenesis by modulating the transforming growth factor- signaling pathway. Read More
Int J Cardiol 2019 Jan 16;275:136-144. Epub 2018 Oct 16.
Dept. Cardiac Thoracic, Vascular Sciences and Public Health, University of Padua, Italy. Electronic address:
Introduction: We investigated the effects of human amniotic fluid stem cells (hAFS) and rat adipose tissue stromal vascular fraction GFP-positive cells (rSVC-GFP) in a model of cardio-renal syndrome type II (CRSII).
Methods And Results: RHF was induced by monocrotaline (MCT) in 28 Sprague-Dawley rats. Three weeks later, four million hAFS or rSVC-GFP cells were injected via tail vein. Read More
Anal Chem 2018 Nov 30. Epub 2018 Nov 30.
Cardiorenal syndrome (CRS) has posed tremendous challenges in patient management, and the detection of serum biomarkers may provide opportunities for early diagnosis and effective treatment. Herein, we introduce a novel surface-enhanced Raman scattering (SERS)-based sandwich immunoassay platform to simultaneously detect cardiac troponin I (cTnI), N-terminal prohormone of brain natriuretic peptide (NT-ProBNP) and neutrophil gelatinase-associated lipocalin (NGAL) for the early diagnosis of CRS by using Raman reporter molecules-labeled Ag-Au nanostars (Ag-Au NSs) as nanotags and three-dimensional ordered macroporous (3DOM) Au-Ag-Au plasmonic array as substrate. The Ag-Au NSs prepared by galvanic replacement feature bimetallic composition and multi-branched structure so that exhibit high SERS stability and enhancement. Read More
J Cardiovasc Pharmacol 2018 Nov 22. Epub 2018 Nov 22.
Department of Anaesthesia and Intensive Care Medicine, San Gerardo Hospital, Monza, Italy.
Levosimendan is an inodilator that promotes cardiac contractility primarily via calcium sensitization of cardiac troponin C and vasodilatation via opening of adenosine triphosphate-sensitive potassium (KATP) channels in vascular smooth muscle cells; the drug also exerts organ-protective effects via a similar effect on mitochondrial KATP channels.This pharmacological profile identifies levosimendan as a drug that may have applications in a wide range of critical illness situations encountered in intensive care unit medicine: hemodynamic support in cardiogenic or septic shock; weaning from mechanical ventilation or from extracorporeal membrane oxygenation; and in the context of cardiorenal syndrome.This review, authored by experts from 9 European countries (Austria, Belgium, Czech republic, Finland, France, Germany, Italy, Sweden, and Switzerland) examines the clinical and experimental data for levosimendan in these situations and concludes that, in most instances, the evidence is affirmative and encouraging, which is not the case with other cardio- and vasoactive drugs routinely used in the intensive care unit. Read More
Cardiorenal Med 2018 Nov 28;9(1):61-68. Epub 2018 Nov 28.
Nephrology, Dialysis, and Transplantation, University of Genoa, Policlinico San Martino, Genoa,
Background: Although heart failure is the most prevalent cardiovascular disease associated with adverse outcome in chronic kidney disease (CKD) and after kidney transplantation, left ventricular (LV) systolic function is often preserved in renal patients. The aim of this study was to evaluate global longitudinal strain (GLS), which is reportedly a more accurate tool for detecting subclinical LV systolic dysfunction, in patients with various degrees of renal function impairment, including kidney transplant recipients (KTRs).
Methods: This prospective study evaluated demographic, clinical, and ultrasound data, including the assessment of LV GLS and mitral E peak velocity and averaged ratio of mitral to myocardial early velocities (E/e'), of 70 consecutive renal patients (20 with stage 2-4 CKD, 25 with end-stage renal disease on hemodialysis [HD], and 25 KTRs). Read More
JAMA Cardiol 2018 Nov 28. Epub 2018 Nov 28.
Cardiovascular Translational Research Center, University of South Carolina School of Medicine, Columbia.
Importance: The standard pharmacotherapy for heart failure (HF), particularly HF with reduced ejection fraction (HFrEF), is primarily through the use of receptor antagonists, notably inhibition of the renin-angiotensin system by either angiotensin-converting enzyme inhibition or angiotensin II receptor blockade (ARB). However, the completed Prospective Comparison of ARNI With an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial identified that the use of a single molecule (sacubitril/valsartan), which is an ARB and the neutral endopeptidase inhibitor (NEPi) neprilysin, yielded improved clinical outcomes in HFrEF compared with angiotensin-converting enzyme inhibition alone.
Observations: This review examined specific bioactive signaling pathways that would be potentiated by NEPi and how these would affect key cardiovascular processes relevant to HFrEF. Read More
Pol J Vet Sci 2018 Sep;21(3):507-515
Department of Veterinary Medicine (DIMEVET), University of Milan, via Celoria 10, 20133 Milan, Italy.
In humans, iron deficiency represents a relevant occurrence in heart failure (HF), with or without anaemia, and is associated with the worst outcome. Moreover, chronic kidney disease (CKD) is a well-known comorbidity of HF and is strongly associated with the risk of developing anaemia. The most common cause of HF in dogs is myxomatous mitral valve disease (MMVD). Read More
Phytomedicine 2018 Dec 19;51:7-19. Epub 2018 May 19.
Laboratório de Eletrofisiologia e Farmacologia Cardiovascular, Faculdade de Ciências da Saúde, Universidade Federal da Grande Dourados, Rodovia Dourados-Itahum, km 12, P.O. Box 533, 79.804-970, Dourados, MS, Brazil. Electronic address:
Background: One of the medicinal plants widely used by the population in the treatment of hypertension, atherosclerosis and circulatory disorders is Cuphea carthagenensis (Jacq.) J.F. Read More
Biomed Pharmacother 2018 Nov 17;110:37-46. Epub 2018 Nov 17.
Department of Anatomy and Embryology, Faculty of Medicine, Zagazig University, Egypt. Electronic address:
Background: Cardiorenal crosstalk has gained growing scientific curiosity recently. Clinical observations have approved that heart and kidney performances are intimately interrelated; acute or chronic dysfunction of either is inevitably mirrored on the other. This coexistence usually has the poor prognosis and worsened outcome. Read More
Data Brief 2018 Dec 1;21:1430-1434. Epub 2018 Nov 1.
Dept. Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padua, Padova, Italy.
The data reported in this article are related to the paper entitle "Stem cells transplantation positively modulates the heart-kidney cross talk in Cardiorenal Syndrome Type II" (Vescovo et al., 2019), which analyzed the impact of stem cells injection in cardiorenal syndrome type II. The dataset contains detailed information on apoptosis and cytokines milieu modification after injection of c-Kit-selected human amniotic fluid stem cells (hAFS) or rats vascular progenitor cells (rSVC-GFP group) in an experimental model of CRSII. Read More
PLoS One 2018 19;13(11):e0206830. Epub 2018 Nov 19.
Department of Internal Medicine III, Clinical Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.
Background: In patients with refractory heart failure (HF) peritoneal dialysis (PD) is associated with improved functional status and decrease in hospitalization. However, previous studies did not focus on right ventricular dysfunction as an important pathophysiologic component of cardiorenal syndrome.
Methods: In a prospective cohort study PD was started in 40 patients with refractory right HF (with/without left HF). Read More
Cardiorenal Med 2018 11 14;9(1):51-60. Epub 2018 Nov 14.
Division of Nephrology, Department of Medicine, Einstein Medical Center, Philadelphia, Pennsylvania, USA.
Background: Kidney transplantation (KT) is the treatment of choice for end-stage kidney disease. Cardiovascular disease is a major determinant of morbidity and mortality in patients with KT. Temporal trends in perioperative cardiovascular outcomes after KT are understudied, especially in light of an aging KT waitlist population. Read More
J Am Soc Nephrol 2018 Dec 12;29(12):2890-2899. Epub 2018 Nov 12.
Sydney School of Public Health, Faculty of Medicine and Health, Sydney, Australia;
Background: The comparative effectiveness of treatment with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or their combination in people with albuminuria and cardiovascular risk factors is unclear.
Methods: In a multicenter, randomized, open label, blinded end point trial, we evaluated the effectiveness on cardiovascular events of ACE or ARB monotherapy or combination therapy, targeting BP<130/80 in patients with moderate or severe albuminuria and diabetes or other cardiovascular risk factors. End points included a primary composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for cardiovascular causes and a revised end point of all-cause mortality. Read More
JACC Heart Fail 2018 Nov 5. Epub 2018 Nov 5.
Department of Medicine, Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Objectives: This study sought to characterize the course of decongestion among patients hospitalized for acute heart failure (AHF) by history of atrial fibrillation (AF) and/or atrial flutter (AFL).
Background: AF/AFL and chronic heart failure (HF) commonly coexist. Little is known regarding impact of AF/AFL on relief of congestion among patients who develop AHF. Read More
Cardiorenal Med 2018 Nov 8;9(1):41-50. Epub 2018 Nov 8.
Medical Faculty, University of Maribor, Maribor, Slovenia.
Background: Chronic kidney disease (CKD) is a well-known mortality risk factor. The subendocardial viability ratio (SEVR) is one of the pulse wave analysis parameters that constitutes a non-invasive measure of coronary perfusion. We aimed to assess the prognostic value of the SEVR for cardiovascular outcome in non-dialysis CKD patients. Read More
Cardiorenal Med 2018 Nov 7;9(1):31-40. Epub 2018 Nov 7.
Background/aims: Cardiac surgery-associated acute kidney injury (CSA-AKI) is one of the most common postoperative complications in intensive care medicine. Baicalin has been shown to have anti-inflammatory and antioxidant roles in various disorders. We aimed to test the protective effects of baicalin on CSA-AKI using a rat model. Read More
Biomed Pharmacother 2019 Jan 4;109:658-670. Epub 2018 Nov 4.
Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan; Institute for Translational Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan; Center for Shockwave Medicine and Tissue Engineering, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 83301, Taiwan; Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan; Department of Nursing, Asia University, Taichung 41354, Taiwan. Electronic address:
This study tested the hypothesis that early administration of empagliflozin (Empa), an inhibitor of glucose recycling in renal tubules, could preserve heart function in cardiorenal syndrome (CRS) in rat. Chronic kidney disease (CKD) was caused by 5/6 subtotal nephrectomy and dilated cardiomyopathy (DCM) by doxorubicin (DOX) treatment. In vitro results showed that protein expressions of cleaved-caspase3 and autophagy activity at 24 h/48 h in NRK-52P cells were significantly upregulated by para-Creso treatment; these were significantly downregulated by Empa treatment. Read More
J Cardiovasc Dev Dis 2018 Nov 3;5(4). Epub 2018 Nov 3.
University Cardiology Unit, Cardiothoracic Department, Policlinic University Hospital, Piazza Giulio Cesare 11, 70124 Bari, Italy.
Aim Of The Study: In chronic heart failure (CHF) patients, renal congestion plays a key role in determining the progression of renal dysfunction and a worse prognosis. The aim of this study was to define the role of Doppler venous patterns reflecting renal congestion that predict heart failure progression.
Methods: We enrolled outpatients affected by CHF, in stable clinical conditions and in conventional therapy. Read More
Cardiovasc J Afr 2018 Sep/Oct;29(5):331-334
Division of Cardiology, University of Khartoum, Khartoum, Sudan.
Background: In response to the call by the World Health Organisation to reduce premature deaths from non-communicable diseases by 25% by the year 2025 (25×25), the Pan-African Society of Cardiology (PASCAR), in partnership with several organisations, including the World Heart Federation, have developed an urgent 10-point action plan to improve detection, treatment and control of hypertension in Africa. Priority six of this action plan is to promote a task-shifting/task-sharing approach in the management of hypertension.
Aim: This capacity-building initiative aims to enhance the knowledge, skills and core competences of primary healthcare physicians in the management of hypertension and related complications. Read More
Int Heart J 2018 Nov 5;59(6):1425-1431. Epub 2018 Nov 5.
Department of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine, Kagawa University.
For atherosclerotic cardiovascular diseases (ACD), gene therapy may be a potential therapeutic strategy; however, lack of effective and safe methods for gene delivery to atherosclerotic plaques have limited its potential therapeutic applications. To overcome this limitation, we developed a novel antibody-based gene delivery system (anti-HB-EGF/NA vector) by chemically crosslinking antibodies against human heparin-binding epidermal growth factor-like growth factor (HB-EGF). It has been shown to be excessively expressed in human atherosclerotic plaques and NeutrAvidin (NA) for conjugating biotinylated siRNA. Read More
Sci Rep 2018 Oct 31;8(1):16087. Epub 2018 Oct 31.
Center for Systems Biology, Program in Membrane Biology, Division of Nephrology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
Cardiovascular disease constitutes the leading cause of mortality in patients with chronic kidney disease (CKD) and end-stage renal disease. Despite increasing recognition of a close interplay between kidney dysfunction and cardiovascular disease, termed cardiorenal syndrome (CRS), the underlying mechanisms of CRS remain poorly understood. Here we report the development of pathological cardiac hypertrophy and fibrosis in early stage non-uremic CKD. Read More
Cardiorenal Med 2018 10 31;9(1):22-30. Epub 2018 Oct 31.
Department of Cardiology, China-Japan Friendship Hospital, Beijing, China
Purpose: Cardiac valve calcification (VC) is very common in patients on hemodialysis. However, the definite effect of VC on left ventricular (LV) geometry and function in this population is unknown, especially when LV ejection fraction (LVEF) is normal. The aim of this study was to determine the effect of VC on LV geometry and function in long-term hemodialysis patients by conventional echocardiography and two-dimensional speckle tracking echocardiography (2D-STE). Read More
J Am Heart Assoc 2018 Oct;7(19):e009162
3 Clinical Atherosclerosis Research Laboratory Division of Cardiology University of Washington Seattle WA.
Background Cardiorenal syndrome type 1 ( CRS 1) as a complication of acute myocardial infarction can lead to adverse outcomes, and a method for early detection is needed. This study investigated the individual and integrated effectiveness of amino-terminal pro-brain natriuretic peptide (Pro-BNP), estimated glomerular filtration rate (eGFR), and high-sensitivity C-reactive protein (CRP) as predictive factors for CRS 1 in patients with acute myocardial infarction. Methods and Results In a retrospective analysis of 2094 patients with acute myocardial infarction, risk factors for CRS 1 were analyzed by logistic regression. Read More
J Am Heart Assoc 2018 Oct;7(19):e009961
1 Department of Anesthesiology and Intensive Care Montreal Heart Institute Université de Montréal Montreal Quebec Canada.
Background Acute kidney injury ( AKI ) after cardiac surgery is associated with adverse outcomes. Venous congestion can impair kidney function, but few tools are available to assess its impact at the bedside. The objective of this study was to determine whether portal flow pulsatility and alterations in intrarenal venous flow assessed by Point-Of-Care ultrasound are associated with AKI after cardiac surgery. Read More
J Am Heart Assoc 2018 Oct;7(20):e009077
1 TIMI Study Group Division of Cardiovascular Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA.
Background Cystatin C (Cys-C) is a marker of renal function that has shown prognostic value for cardiovascular risk stratification across different patient populations. The incremental value of Cys-C beyond established cardiac and renal biomarkers remains incompletely explored. Methods and Results SOLID - TIMI 52 (Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52; www. Read More
Ultrasound Int Open 2018 Oct 25;4(4):E142-E148. Epub 2018 Oct 25.
Universitat zu Lubeck Sektion Medizin, Medical Clinic I, Lubeck, Germany.
Objective: Diagnosing cardiorenal syndrome (CRS) in patients with chronic kidney disease (CKD) continues to remain challenging in outpatient practice. In this study, we investigate whether a newly developed venous velocity ultrasound index (VVI) can differentiate between patients with CRS and patients with CKD of other cause or normal renal function (NRF).
Methods: Patients with CRS (n 30), CKD (n=30), and NRF (n=30) were included in the study. Read More
J Am Heart Assoc 2018 Aug;7(16):e008455
3 Department of Transplantation Sahlgrenska University Hospital Gothenburg Sweden.
Background The management of the cardiorenal syndrome in advanced heart failure is challenging, and the role of inotropic drugs has not been fully defined. Our aim was to compare the renal effects of levosimendan versus dobutamine in patients with heart failure and renal impairment. Methods and Results In a randomized double-blind study, we assigned patients with chronic heart failure (left ventricular ejection fraction <40%) and impaired renal function (glomerular filtration rate <80 mL/min per 1. Read More
Cardiorenal Med 2018 Oct 25;9(1):8-21. Epub 2018 Oct 25.
Department of Nephrology and Dialysis, ASTT Lariana, S. Anna Hospital, Como, Italy.
Chronic hyperkalemia (HK) is a serious medical condition that often manifests in patients with chronic kidney disease (CKD) and heart failure (HF) leading to poor outcomes and necessitating careful management by cardionephrologists. CKD, HF, diabetes, and renin-angiotensin-aldosterone system inhibitors use is known to induce HK. Current therapeutic options are not optimal, as pointed out by a large number of CKD and HF patients with HK. Read More
Georgian Med News 2018 Sep(282):65-73
Government Institution L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine". Department of Clinical Pharmacology and Pharmacogenetics of Non-Communicable Diseases, Kharkiv, Ukraine.
Aim - to study the predictors of cardiovascular events in patients with chronic heart failure (CHF) with preserved left ventricular ejection fraction role of traditional and non-traditional risk factors, to analyze the prognostic role of hyponatremia. Analysis of the clinical features of CHF was provided by retrospective research of medical cards in 308 patients, with endpoint verification during long-term period from 2010 to 2015. Among the examined patients 81 addmitted to the intensive care unit. Read More
Circ Res 2018 Aug;123(5):590-600
From the Cardiovascular Center of Excellence and Department of Pharmacology, LSU Health Science Center, New Orleans, LA.
Hydrogen sulfide (HS)-a potent gaseous signaling molecule-has emerged as a critical regulator of cardiovascular homeostasis. HS is produced enzymatically by 3 constitutively active endogenous enzymes in all mammalian species. Within the past 2 decades, studies administering HS-donating agents and the genetic manipulation of HS-producing enzymes have revealed multiple beneficial effects of HS, including vasodilation, activation of antiapoptotic and antioxidant pathways, and anti-inflammatory effects. Read More
Hypertension 2018 Oct;72(4):832-833
Physiology and Biophysics (B.T.A.), University of Mississippi-Medical Center, Jackson, MS.
Circulation 2018 Aug;138(9):929-944
Universite de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, France (F.Z., P.R.).
Cardiorenal syndromes have been categorized into 5 clinical subtypes based on which organ is perceived to be the primary precipitant of the vicious and interrelated cycle of declining function in both organs. This clinical classification has broadened interest in cardiorenal interactions, but it is merely descriptive, does not rely on or inform predominant pathophysiology, and has produced little change in either practice or the research agenda. In contrast, recent scientific work identifies common pathophysiological pathways for several categories of cardiorenal syndromes, suggesting a unifying pathogenesis. Read More
Circ Genom Precis Med 2018 Sep;11(9):e002213
Departments of Internal Medicine, University of Michigan, Ann Arbor (B.G.B., R.J.A., S.L.H., J.B.B.).
Background mRNA in urine supernatant (US-mRNA) might encode information about renal and cardiorenal pathophysiology, including hypertension. H, whether the US-mRNA transcriptome reflects that of renal tissues and whether changes in renal physiology are detectable using US-mRNA is unknown. Methods We compared transcriptomes of human urinary extracellular vesicles and human renal cortex. Read More
PLoS One 2018 23;13(10):e0206174. Epub 2018 Oct 23.
Department of Internal Medicine, Division of Endocrinology, Maastricht University Medical Center, Maastricht, The Netherlands.
Background: Small-molecules that disrupt the binding between glucokinase and glucokinase regulatory protein (GKRP) in the liver represent a potential new class of glucose-lowering drugs. It will, however, take years before their effects on clinically relevant cardiovascular endpoints are known. The purpose of this study was to estimate the effects of these drugs on cardiorenal outcomes by studying variants in the GKRP gene (GCKR) that mimic glucokinase-GKRP disruptors. Read More
Clin Transplant 2018 Nov 23;32(11):e13417. Epub 2018 Oct 23.
VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania.
Complications arising from a functional arteriovenous fistula (AVF) in successful kidney transplant recipients (KT) have been overlooked despite some reports of its deleterious effect on heart, lungs, and kidney allograft. As such, there is no consensus regarding management of AVF after renal transplantation. We report Cardio-Renal Syndrome Type 5 in kidney transplant recipients who presented with a clinical syndrome of shortness of breath, edematous state, kidney allograft dysfunction, and high pulmonary pressure 3-8 months after successful transplantation. Read More
J Cardiothorac Vasc Anesth 2018 Sep 12. Epub 2018 Sep 12.
Department of Anesthesiology and Perioperative Medicine, Oregon Health and Science University, Portland, OR; Portland VA Medical Center, Portland, OR.
Objective: An association between central venous pressure and acute kidney injury (AKI) has been observed following cardiac surgery, but it is unknown whether this reflects intravascular volume status or impaired right ventricular (RV) myocardial performance. This study was performed to test the hypothesis that decreased RV peak longitudinal strain (PLSS), as measured by 2-dimensional speckle-tracking echocardiography, is associated with AKI following cardiac surgery.
Design: Retrospective observational cohort study. Read More
ESC Heart Fail 2018 Oct 12. Epub 2018 Oct 12.
Mohammed Bin Khalifa Cardiac Centre, Manama, Bahrain.
Aims: This study aims to evaluate the incidence and impact of cardiorenal anaemia syndrome (CRAS) on all-cause mortality in acute heart failure (AHF) patients stratified by left ventricular ejection fraction (LVEF) status in the Middle East.
Methods And Results: Data were analysed from 4934 consecutive patients admitted to 47 hospitals in seven Middle Eastern countries (Saudi Arabia, Oman, Yemen, Kuwait, United Arab Emirates, Qatar, and Bahrain) with AHF from February to November 2012. CRAS was defined as AHF with estimated glomerular filtration rate of <60 mL/min and low haemoglobin (<13 g/dL for men or <12 g/dL for women). Read More
Exp Physiol 2018 Dec 5;103(12):1593-1602. Epub 2018 Nov 5.
Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
New Findings: What is the central question of this study? The aim was to determine the renoprotective effects of serelaxin in the setting of chronic heart failure. What are the main findings and its importance? Our data indicate that serelaxin can reduce renal fibrosis and inflammation in experimental heart failure. Currently, there are no effective treatments to rescue renal function in heart failure patients, and our data suggest that serelaxin might have the potential to reduce renal fibrosis and inflammation in heart failure. Read More
Adv Chronic Kidney Dis 2018 Sep;25(5):454-467
Division of Nephrology, Department of Medicine, Duke University, Durham, NC 27705. Electronic address:
Chronic diseases of the heart and of the kidneys commonly coexist in individuals. Certainly combined and persistent heart and kidney failure can arise from a common pathologic insult, for example, as a consequence of poorly controlled hypertension or of severe diffuse arterial disease. However, strong evidence is emerging to suggest that cross talk exists between the heart and the kidney. Read More
Adv Chronic Kidney Dis 2018 Sep;25(5):443-453
Henry Ford Hospital, Advanced Heart Failure & Cardiac Transplant Program, Detroit, MI.
Heart failure (HF) is extremely prevalent and for those with end-stage (stage D) disease, 1-year survival is only 25-50%. Several studies have captured the mortality impact of kidney disease on patients with HF, and measures of kidney function are a component of many HF risk stratification scores. The management of advanced HF complicated by cardiorenal syndrome (CRS) is challenging, and irreversible kidney failure often limits patient candidacy for advanced HF therapies, such as transplant or left ventricular assist device therapy. Read More
Adv Chronic Kidney Dis 2018 Sep;25(5):434-442
Division of Nephrology, Hypertension, and Renal Transplantation, University of Florida, Gainesville, FL; and Advocate Heart Institute, Naperville, IL. Electronic address:
Acute decompensated heart failure has the highest rate of hospital readmission among all medical conditions and portends a significant financial burden on health care system. Congestion, the hallmark of acute decompensated heart failure, represents the primary reason for hospitalization and the driver of adverse outcomes in these patients. Although diuretic-based medical regimens remain the mainstay of management of acute decompensated heart failure, they often show suboptimal efficacy and safety profiles in this setting. Read More